Comparison of Time to Therapeutic aPTT in Patients Who Received Continuous Unfractionated Heparin After Implementation of Pharmacy-wide Intervention Alerts
- PMID: 27698506
- PMCID: PMC5030878
- DOI: 10.1310/hpj5108-656
Comparison of Time to Therapeutic aPTT in Patients Who Received Continuous Unfractionated Heparin After Implementation of Pharmacy-wide Intervention Alerts
Abstract
Background: For patients on continuous IV unfractionated heparin (UFH), failing to achieve a therapeutic aPTT by 24 hours can be associated with increased morbidity. A pharmacy clinical surveillance system (PCSS) subtherapeutic aPTT alert was implemented at our institution to improve achievement of therapeutic aPTT goals by 24 hours. Objective: The primary objective was the time to achieve the minimum goal aPTT before and after the alert implementation. The secondary objectives were to examine the percentage of patients who achieved the minimum goal aPTT by 24 hours and the number of dose changes to achieve the minimum goal aPTT. Methods: A single-center retrospective study was conducted to include all adult inpatients receiving a continuous UFH infusion during a 3-month period prior to the implementation of a subtherapeutic aPTT alert and a 3-month period after implementation. Results: 317 patients were included in the analysis. The average time to achieve the minimum goal aPTT was 21.8 hours prior to alert implementation and 15.4 hours after implementation (p = .002). The percent of patients who achieved the minimum goal aPTT by 24 hours was 65.7% prior to alert implementation and 82.4% after implementation (p = .035). The average number of dose changes necessary to achieve aPTT value to the minimum goal aPTT prior to alert implementation was 1.67 and 1. 98 after implementation (p = .68). Conclusion: This analysis showed that implementation of a PCSS subtherapeutic aPTT alert for patients on continuous UFH infusions may ensure patients reach goal aPTT faster and facilitate a higher percent of patients who achieve the minimum goal aPTT by 24 hours.
Keywords: aPTT; alert; heparin; monitoring; pharmacy clinical surveillance system.
Figures
Similar articles
-
Activated partial thromboplastin time versus antifactor Xa heparin assay in monitoring unfractionated heparin by continuous intravenous infusion.Ann Pharmacother. 2011 Jul;45(7-8):861-8. doi: 10.1345/aph.1Q161. Epub 2011 Jun 28. Ann Pharmacother. 2011. PMID: 21712506
-
Higher Maximum Doses and Infusion Rates Compared with Standard Unfractionated Heparin Therapy Are Associated with Adequate Anticoagulation without Increased Bleeding in Both Obese and Nonobese Patients with Cardiovascular Indications.Pharmacotherapy. 2017 Apr;37(4):393-400. doi: 10.1002/phar.1904. Epub 2017 Mar 10. Pharmacotherapy. 2017. PMID: 28107569
-
Antifactor Xa levels vs. activated partial thromboplastin time for monitoring unfractionated heparin. A pilot study.J Clin Pharm Ther. 2016 Oct;41(5):499-502. doi: 10.1111/jcpt.12415. Epub 2016 Jul 6. J Clin Pharm Ther. 2016. PMID: 27381025
-
Monitoring of unfractionated heparin in critically ill patients.Neth J Med. 2013 Nov;71(9):466-71. Neth J Med. 2013. PMID: 24218420 Review.
-
Antifactor Xa levels versus activated partial thromboplastin time for monitoring unfractionated heparin.Pharmacotherapy. 2012 Jun;32(6):546-58. doi: 10.1002/j.1875-9114.2011.01049.x. Epub 2012 Apr 24. Pharmacotherapy. 2012. PMID: 22531940 Review.
Cited by
-
Evaluation of Antifactor-Xa Heparin Assay and Activated Partial Thromboplastin Time Values in Patients on Therapeutic Continuous Infusion Unfractionated Heparin Therapy.Clin Appl Thromb Hemost. 2019 Jan-Dec;25:1076029619876030. doi: 10.1177/1076029619876030. Clin Appl Thromb Hemost. 2019. PMID: 31530176 Free PMC article.
-
Therapeutic inefficacy of protocol driven intravenous unfractionated heparin infusion in the current era.Am Heart J Plus. 2023 Sep 5;34:100322. doi: 10.1016/j.ahjo.2023.100322. eCollection 2023 Oct. Am Heart J Plus. 2023. PMID: 38510949 Free PMC article.
References
-
- Eikelboom J, Hirsh J. Monitoring unfractionated heparin with the aPTT: Time for a fresh look. Thromb Haemost. 2006;96:547–552. - PubMed
-
- Hirsh J. Low-molecular-weight heparin: A review of the results of recent studies of the treatment of venous thromboembolism and unstable angina. Circulation. 1998;98(15):1575–1582. - PubMed
-
- Olson J, Arkin C, Brandt J et al. College of American Pathologists Conference XXXI on laboratory monitoring of anticoagulant therapy: Laboratory monitoring of unfractionated heparin therapy. Arch Pathol Lab Med. 1998;122(9):782–798. - PubMed
-
- Hirsh J, Anand SS, Halperin JL et al. Guide to anticoagulant therapy: Heparin: A statement for healthcare professionals from the American Heart Association. Circulation. 2001;103(24):2994–3018. - PubMed
-
- Basu D, Gallus A, Hirsh J, Cade J. A prospective study of the value of monitoring heparin treatment with the activated partial thromboplastin time. N Engl J Med. 1972;287:324–327. - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources